Read our Recent Headlines


Wizard of Ops – AXON trading idea

Everyone in the world knows that there’s a huge Alzheimer’s catalyst coming up for AXON.  As such, the options are priced pretty crazy.  October options are priced as if $50.

August 18 Biotech Update

The whole market is looking heavy and the IWM broke below key support. The sector is not going to be able to hold up if this continues but luckily there.

August 17 Biotech Update

There is nothing to dissuade me that risk on is creeping back into the market as North Korea is fading into the background (for how long who knows but that.

Dave-Trading – September 2017

*** David Sobek is a disciplined value investor.  Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.

August 16 Biotech Update

The recovery continues as risk-on seems to be heading back into the market. Part of me sees this as what I expected in terms of a sell off to test.

August 14 Biotech Update

We survived the weekend without a nuclear holocaust so I guess that is good for a relief rally. That seems a little misplaced in that the weather has been bad.

August 11 Biotech Update

The macro risks are helping to bring down the sector and we are just about at those breakout levels that I have been talking about. Of course, I also noted.

Introduction


Quick Facts

10

Analysts

500

Clients

22k

Followers

900

Reports

2.7k

Comments

5

Years

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!